Table 1:

Potential interactions between antimalarial and antiretroviral drugs.

Antimalarial drugs	Antiretroviral drugs	Potential interactions
Quinine	EFV, NVP	Reduced quinine concentrations
Quinine	PI	Reduced quinine concentrations
Atovaquone/Proguanil	RTV, LPV/r, ATV/r, IDV, EFV	Reduced atovaquone/proguanil concentrations
Atovaquone/Proguanil	IDV	Reduced IDV concentrations
Atovaquone/Proguanil	AZT	Increased AZT concentrations Increased risk for anaemia
Mefloquine	RTV	Reduced RTV concentrations
Mefloquine	EFV, NVP	Reduced mefloquine concentrations
Lumefantrine	PI	Increased lumefantrine concentrations Prolongation of QT interval
Lumefantrine	NVP, EFV, DLV	Reduced lumefantrine concentrations Prolongation of QT interval
Halofantrine	PI	Increased halofantrine concentrations Prolongation of QT interval
Halofantrine	NVP, EFV, DLV	Reduced halofantrine concentrations Prolongation of QT interval
Amodiaquine + artesunate	EFV	Increased amodiaquine concentrations Increased transaminase levels
Chloroquine	RTV	Alteration of antimalarial drug metabolism
Pyrimethamine	RTV	Alteration of antimalarial drug metabolism
Sulfadoxine-pyrimethamine	RTV	Alteration of antimalarial drug metabolism
Sulfadoxine-pyrimethamine	NVP	Possible adverse cutaneous or hepatic reactions
Sulfadoxine-pyrimethamine	AZT	Increased risk for anaemia
Sulfadoxine-pyrimethamine	Co-trimoxazole	Increased risk of severe adverse cutaneous or hepatic reactions
Artemisinin	PI	Alteration of artemisinin metabolism
Dapsone	SQV	Alteration of dapsone metabolism

Modified by Flateau C, Lancet Infect Dis, 2011; Skinner-Adams TS, Trends Parasitol, 2008; Khoo S, AIDS, 2005.¹¹,¹³,⁶⁹

EFV: efavirenz; NVP: nevirapine; PI: protease inhibitors; RTV: ritonavir; LPV: lopinavir boosted by ritonavir; ATV/r: atazanavir boosted by ritonavir; IDV: indinavir; AZT: zidovudine; DLV: delavirdine; SQV: saquinavir.